South Texas Money Management Ltd. raised its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 2.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 353,598 shares of the medical research company’s stock after purchasing an additional 8,782 shares during the quarter. Edwards Lifesciences Corporation makes up approximately 2.1% of South Texas Money Management Ltd.’s portfolio, making the stock its 12th largest holding. South Texas Money Management Ltd. owned 0.17% of Edwards Lifesciences Corporation worth $41,809,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Sabal Trust CO lifted its holdings in Edwards Lifesciences Corporation by 0.5% during the second quarter. Sabal Trust CO now owns 2,934 shares of the medical research company’s stock valued at $347,000 after purchasing an additional 14 shares during the last quarter. Alps Advisors Inc. lifted its holdings in Edwards Lifesciences Corporation by 0.3% during the second quarter. Alps Advisors Inc. now owns 5,102 shares of the medical research company’s stock valued at $603,000 after purchasing an additional 14 shares during the last quarter. Alexandria Capital LLC lifted its holdings in Edwards Lifesciences Corporation by 1.7% during the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after purchasing an additional 19 shares during the last quarter. M Holdings Securities Inc. lifted its holdings in Edwards Lifesciences Corporation by 1.5% during the first quarter. M Holdings Securities Inc. now owns 4,132 shares of the medical research company’s stock valued at $389,000 after purchasing an additional 62 shares during the last quarter. Finally, First Bank & Trust lifted its holdings in Edwards Lifesciences Corporation by 1.7% during the second quarter. First Bank & Trust now owns 4,439 shares of the medical research company’s stock valued at $525,000 after purchasing an additional 76 shares during the last quarter. 82.08% of the stock is currently owned by institutional investors and hedge funds.

In other Edwards Lifesciences Corporation news, VP Larry L. Wood sold 18,960 shares of Edwards Lifesciences Corporation stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $112.58, for a total value of $2,134,516.80. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,600 shares of Edwards Lifesciences Corporation stock in a transaction that occurred on Thursday, June 29th. The stock was sold at an average price of $117.15, for a total value of $656,040.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 182,501 shares of company stock worth $20,847,236. 2.13% of the stock is owned by insiders.

Several equities research analysts have commented on the stock. BidaskClub downgraded shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 13th. Canaccord Genuity reaffirmed a “buy” rating and set a $150.00 price objective on shares of Edwards Lifesciences Corporation in a report on Wednesday, June 28th. Zacks Investment Research raised shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $129.00 price objective on the stock in a report on Thursday, June 1st. Cowen and Company reiterated an “outperform” rating and set a $135.00 price target (up from $130.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Finally, Jefferies Group LLC set a $115.00 price target on Edwards Lifesciences Corporation and gave the company a “buy” rating in a research report on Saturday, May 27th. Six equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $120.75.

Shares of Edwards Lifesciences Corporation (NYSE:EW) traded up 0.30% on Wednesday, reaching $111.61. 190,529 shares of the company’s stock were exchanged. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.75. The company has a 50 day moving average price of $113.80 and a 200 day moving average price of $109.37. The firm has a market cap of $23.57 billion, a PE ratio of 33.85 and a beta of 0.64.

Edwards Lifesciences Corporation (NYSE:EW) last posted its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 EPS for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The company had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $839.16 million. During the same period in the previous year, the firm earned $0.76 EPS. The firm’s revenue was up 10.9% compared to the same quarter last year. Analysts expect that Edwards Lifesciences Corporation will post $3.78 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/09/20/south-texas-money-management-ltd-acquires-8782-shares-of-edwards-lifesciences-corporation-ew.html.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.